Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Ruxolitinib for Tacrolimus-Refractory Facial Vitiligo
NCT06719024Phase 3Recruiting
- Sponsor
- Hospital Authority
- Start
- Nov 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ruxolitinib cream in nonsegmental vitiligo (NSV) (2 arms), sponsored by Hospital Authority. Primary endpoint: Degree of repigmentation at 24 weeks. Started Nov 2024; status: recruiting.
02
Drugs
ruxolitinib cream
03
Conditions
nonsegmental vitiligo (NSV)
Beyond the preview
Go deeper on NCT06719024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06719024.